Epidemiological Clinical Features and Evolution of Gastroduodenal Ulcer Bleeding in a Tertiary Care Hospital in Spain, during the Last Seven Years
Table 3
Outcomes of patients with bleeding episode.
Rebleeding ()
P
Death ()
P
Male gender, n (%)
23 (76.7)
0.5
13 (86.7)
0.2
Age (mean ± SD, years) Range
(39–90)
0.5
(50–99)
0.1
Comorbidities, n (%)
17 (56.7)
0.3
14 (93.3)
<0.01
Drugsa, n (%)
16 (53.3)
0.7
6 (40)
0.2
Prior peptic ulcer, n (%)
5 (16.7)
0.9
1 (6.7)
0.5
Duodenal ulcer, n (%)
19 (63.3%)
0.9
9 (60%)
0.9
Forrest classification, n (%)
High-stigmata signs for rebleedingb
25 (83.3)
<0.01
10 (66.7)
0.6
Death, n (%)
4 (13.3)
0.07
—
—
Rebleeding, n (%)
—
—
4 (26.7)
0.07
Aspirin, non-steroidal anti-inflammatory drugs (NSAID), antiplatelet therapy and/or anticoagulant drugs.
bPatients with gastric and duodenal ulcers were not considered. High-stigmata signs for rebleeding included ulcers classified as Forrest Ia, Ib, IIa and IIb.
